RxDoctor Payments DataLook up a doctor →

Thomas Burke, DO

Dermatology · Newark, DENPI 1881698389

Payments from drug & device makers

$20,539in general payments, 2019–2025

Across 1,279 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • UCB, Inc.$1K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • plus $9K from 36 others

What the payments were for

  • Food & beverage$20,30899%
  • Education$2301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,539 in reported general payments places this provider in the 90th percentile of 23 dermatology providers in Delaware.

See all dermatology providers in Delaware

Medicare billing

Part B allowed, 2024
$806,747
Medicare patients
3,019
Services billed
8,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab67$823,318
Dupixent PenDupilumab180$740,686
Skyrizi PenRisankizumab-Rzaa26$567,442
Cosentyx Sensoready (2 Pens)Secukinumab53$434,207
ErivedgeVismodegib23$368,458
Dupixent SyringeDupilumab64$279,028
StelaraUstekinumab17$276,060
RinvoqUpadacitinib41$258,546
Taltz AutoinjectorIxekizumab37$239,958
TremfyaGuselkumab14$176,982
Cosentyx Unoready PenSecukinumab20$165,044
OtezlaApremilast25$120,840
XolairOmalizumab22$66,866
AdbryTralokinumab-Ldrm13$46,891
Fluorouracil308$20,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya$2,445$453,04331 claims
Genentech USA, Inc.Erivedge$507$368,45823 claims
AbbVieRinvoq$3,266$258,54641 claims
AmgenOtezla$1,224$120,84025 claims
LEO Pharma Inc.Adbry$884$46,89113 claims
Arcutis Biotherapeutics, Inc.Zoryve$228$11,33313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 dermatology providers in Delaware.

Other dermatology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →